nVNS — Non-Invasive Vagus Nerve Stimulation

Non-invasive vagus nerve stimulation (nVNS) delivers transcutaneous current to the vagus nerve — at the neck or the ear — to modulate brainstem and autonomic circuits. It sits in the Electroceuticals / Bioelectronic Medicine family and is evidence-supported for specific headache indications, while being sold widely off-label for HRV and longevity, where the evidence is still frontier. It is a dual-badge entry for exactly that reason.

The real substrate — afferent vagal neuromodulation

The mechanism is real and anatomically defined. Transcutaneous cervical or auricular stimulation drives afferent neuromodulation of brainstem and autonomic circuits, engaging the cholinergic anti-inflammatory pathway along a known vagal route. This is genuine neuromodulation with a defined afferent pathway, not a diffuse “energy” effect — there is a nerve, a current, and a circuit it plausibly reaches. That grounding is what places the cleared uses on solid footing and keeps the off-label uses honestly in the “under study” column rather than the refuted one.

Claim vs evidence — why grade B/C

The evidence is the core of this entry, and it divides by indication. For the cleared headache uses it reaches grade B; for the broad wellness, HRV, and longevity claims it is grade C. Here the record lets us name primary sources. The FDA 510(k) clearances are verifiable through openFDA: K173442 (gammaCore, acute migraine) and K182369 (cluster headache). The pivotal trial behind the cluster-headache indication, PREVA (Gaul et al., Cephalalgia 2016), is available in full text at PMC4853813. A further acute-migraine pivotal trial, PRESTO, is referenced in the dossier but its primary-source URL is not yet locked, so it is named for context rather than cited as a link — the honest move being to omit the URL rather than fabricate one. That is the texture of grade B: real clearances and at least one confirmable pivotal trial for the headache claims, with the broad longevity claims left at C because no comparable controlled evidence supports them.

Why this tier — and the indication-vs-off-label split

nVNS carries a dual badge because the tier attaches to the claim, not the device. For its cleared indications — episodic cluster headache (FDA 2017) and migraine (FDA 2018), via gammaCore — it is Evidence-supported. For broad longevity, HRV, anti-aging, and biohacking use it is Insufficient-evidence: a real substrate whose wider doctrine is unproven but not refuted. Keep the three axes apart: plausibility is high (a defined afferent vagal pathway), the grade is B for headache and C for wellness, and the tier depends entirely on which claim is on the table. A strong cleared indication does not license the off-label ones, and the unproven off-label use does not taint the cleared ones — that is precisely what the split records.

Regulatory by jurisdiction

In the US the clearances are specific and prescription-bound: gammaCore for acute migraine (K173442, decision 2018-01-23) and for cluster headache prevention and acute treatment (K182369, decision 2018-11-27), with episodic acute cluster first cleared in 2017. The device is CE marked in the EU; no registration was found in Russia, China, or Australia. The auricular taVNS consumer devices — Nurosym, Parasym, Pulsetto, Truvaga — occupy the wellness channel rather than these prescription clearances. As always, a 510(k) is market access for a named indication; it is not a warrant for the HRV and longevity claims that dominate the consumer side.

Lineage — the bioelectronic frontier, done right

nVNS belongs to the modern bioelectronic-medicine current (electroCore's gammaCore, cleared in the late 2010s) rather than the older “frequency” ancestry on the lineage page. Within the electrostimulation family it sits beside TENS / microcurrent and the SCENAR / DENAS branch — the Soviet success line — as another case where a defined, dosed effect on real nerves earns regulatory standing for specific uses. It is the well-behaved end of the family: a real pathway, narrow clearances, and a clear marker where the evidence stops.

Keep vs set aside

Keep: real vagal neuromodulation and the cleared headache indications, which are solid. Set aside: the broad “longevity / HRV / anti-aging / biohacking” claims, which are off-label frontier — under study, not established. The neuromodulation is real and the headache clearances are earned; the wider wellness story is not yet backed by the evidence.